Your browser doesn't support javascript.
loading
Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus.
van Zuydam, Natalie R; Ladenvall, Claes; Voight, Benjamin F; Strawbridge, Rona J; Fernandez-Tajes, Juan; Rayner, N William; Robertson, Neil R; Mahajan, Anubha; Vlachopoulou, Efthymia; Goel, Anuj; Kleber, Marcus E; Nelson, Christopher P; Kwee, Lydia Coulter; Esko, Tõnu; Mihailov, Evelin; Mägi, Reedik; Milani, Lili; Fischer, Krista; Kanoni, Stavroula; Kumar, Jitender; Song, Ci; Hartiala, Jaana A; Pedersen, Nancy L; Perola, Markus; Gieger, Christian; Peters, Annette; Qu, Liming; Willems, Sara M; Doney, Alex S F; Morris, Andrew D; Zheng, Yan; Sesti, Giorgio; Hu, Frank B; Qi, Lu; Laakso, Markku; Thorsteinsdottir, Unnur; Grallert, Harald; van Duijn, Cornelia; Reilly, Muredach P; Ingelsson, Erik; Deloukas, Panos; Kathiresan, Sek; Metspalu, Andres; Shah, Svati H; Sinisalo, Juha; Salomaa, Veikko; Hamsten, Anders; Samani, Nilesh J; März, Winfried; Hazen, Stanley L.
Afiliação
  • van Zuydam NR; Pat Macpherson Center for Pharmacogenetics & Pharmacogenomics, Cardiovascular & Diabetes Medicine (N.R.v.Z., C.N.A.P.), School of Medicine, University of Dundee.
  • Ladenvall C; Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine (N.R.v.Z., N.W.R., N.R.R., A. Mahajan, M.I.Mc), University of Oxford, United Kingdom.
  • Voight BF; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Strawbridge RJ; Department of Clinical Sciences, Diabetes & Endocrinology, Lund University Diabetes Center, Malmö, Sweden (C.L., L.G.).
  • Fernandez-Tajes J; Department of Systems Pharmacology & Translational Therapeutics (B.F.V.).
  • Rayner NW; Department of Genetics (B.F.V.).
  • Robertson NR; Institute for Translational Medicine & Therapeutics (B.F.V.).
  • Mahajan A; Cardiovascular Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden (R.J.S., A.H.).
  • Vlachopoulou E; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Goel A; Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine (N.R.v.Z., N.W.R., N.R.R., A. Mahajan, M.I.Mc), University of Oxford, United Kingdom.
  • Kleber ME; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Nelson CP; Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom (N.W.R.).
  • Kwee LC; Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine (N.R.v.Z., N.W.R., N.R.R., A. Mahajan, M.I.Mc), University of Oxford, United Kingdom.
  • Esko T; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Mihailov E; Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine (N.R.v.Z., N.W.R., N.R.R., A. Mahajan, M.I.Mc), University of Oxford, United Kingdom.
  • Mägi R; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Milani L; Transplantation Laboratory, Haartman Institute (E.V.), University of Helsinki, Helsinki, Finland.
  • Fischer K; Wellcome Center for Human Genetics (N.R.v.Z., J.F.T., N.W.R., N.R.R, A. Mahajan, A.G., H.W., A.P.M., M.I.Mc), University of Oxford, United Kingdom.
  • Kanoni S; Division of Cardiovascular Medicine (A.G., H.W.), University of Oxford, United Kingdom.
  • Song C; Department of Cardiovascular Sciences, University of Leicester (C.P.N., N.J.S.).
  • Hartiala JA; NIHR Leicester Biomedical Research Center, Glenfield Hospital, Leicester, United Kingdom (C.P.N., N.J.S.).
  • Pedersen NL; Duke Molecular Physiology Institute, Duke University, Durham, NC (L.C.K., S.H.S.).
  • Perola M; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Gieger C; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Peters A; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Qu L; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Willems SM; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Doney ASF; Center for Genomic Health (S.K.), Queen Mary University of London, London, United Kingdom.
  • Morris AD; William Harvey Research Institute, Barts & the London Medical School (S.K., P.D.), Queen Mary University of London, London, United Kingdom.
  • Zheng Y; Broad Institute of MIT & Harvard, Cambridge (S.K.).
  • Sesti G; Cardiology Division, Center for Human Genetic Research (S.K.), Massachusetts General Hospital & Harvard Medical School, Boston, MA.
  • Hu FB; Cardiovascular Research Center (S.K.), Massachusetts General Hospital & Harvard Medical School, Boston, MA.
  • Qi L; Department of Medical Sciences, Molecular Epidemiology & Science for Life Laboratory (J.K., C.S., E.I.).
  • Laakso M; Center for Computational Biology & Bioinformatics, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, India (J.K.).
  • Thorsteinsdottir U; Department of Medical Sciences, Molecular Epidemiology & Science for Life Laboratory (J.K., C.S., E.I.).
  • Grallert H; Department of Immunology, Genetics and Pathology, Medical Genetics & Genomics, Uppsala University, Uppsala, Sweden (C.S.).
  • van Duijn C; Framingham Heart Study (C.S.).
  • Reilly MP; Population Sciences Branch, National Heart, Lung & Blood Institute, National Institute of Health, Framingham, MA (C.S.).
  • Ingelsson E; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (J.A.H.).
  • Deloukas P; Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden (N.L.P.).
  • Kathiresan S; Research Program for Clinical & Molecular Metabolism, Faculty of Medicine (M.P.), University of Helsinki, Helsinki, Finland. Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Metspalu A; Estonian Genome Center (T.E., E.M., R.M., L.M., K.F., M.P., A. Metspalu), University of Tartu, Tartu, Estonia.
  • Shah SH; National Institute for Health and Welfare, Helsinki, Finland (M.P., V.S.).
  • Sinisalo J; German Center for Diabetes Research (DZD), München-Neuherberg (C.G., A.P., H.G.).
  • Salomaa V; Clinical Cooperation Group Type 2 Diabetes (C.G., H.G.), Helmholtz Zentrum München, Neuherberg, Germany.
  • Hamsten A; German Research Center for Environmental Health & Institute of Genetic Epidemiology (C.G., A.P.), Helmholtz Zentrum München, Neuherberg, Germany.
  • Samani NJ; German Center for Diabetes Research (DZD), München-Neuherberg (C.G., A.P., H.G.).
  • März W; German Research Center for Environmental Health & Institute of Genetic Epidemiology (C.G., A.P.), Helmholtz Zentrum München, Neuherberg, Germany.
  • Hazen SL; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (A.P.).
Circ Genom Precis Med ; 13(6): e002769, 2020 12.
Article em En | MEDLINE | ID: mdl-33321069
ABSTRACT

BACKGROUND:

Coronary artery disease (CAD) is accelerated in subjects with type 2 diabetes mellitus (T2D).

METHODS:

To test whether this reflects differential genetic influences on CAD risk in subjects with T2D, we performed a systematic assessment of genetic overlap between CAD and T2D in 66 643 subjects (27 708 with CAD and 24 259 with T2D). Variants showing apparent association with CAD in stratified analyses or evidence of interaction were evaluated in a further 117 787 subjects (16 694 with CAD and 11 537 with T2D).

RESULTS:

None of the previously characterized CAD loci was found to have specific effects on CAD in T2D individuals, and a genome-wide interaction analysis found no new variants for CAD that could be considered T2D specific. When we considered the overall genetic correlations between CAD and its risk factors, we found no substantial differences in these relationships by T2D background.

CONCLUSIONS:

This study found no evidence that the genetic architecture of CAD differs in those with T2D compared with those without T2D.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Predisposição Genética para Doença / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Circ Genom Precis Med Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Predisposição Genética para Doença / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Circ Genom Precis Med Ano de publicação: 2020 Tipo de documento: Article